FLUOR-OP Drug Patent Profile
✉ Email this page to a colleague
When do Fluor-op patents expire, and what generic alternatives are available?
Fluor-op is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in FLUOR-OP is fluorometholone. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluorometholone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fluor-op
A generic version of FLUOR-OP was approved as fluorometholone by AMNEAL on January 9th, 2024.
Summary for FLUOR-OP
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Patent Applications: | 4,355 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FLUOR-OP at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for FLUOR-OP
US Patents and Regulatory Information for FLUOR-OP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | FLUOR-OP | fluorometholone | SUSPENSION/DROPS;OPHTHALMIC | 070185-001 | Feb 27, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |